Targeting the KMT2A protein subcomplex epigenetically diminished the tumorigenic characteristic of pancreatic adenosquamous carcinomas, implying the capability for KMT2A inhibition as an adjunct to chemotherapy and eventually enhancing clinical outcomes for pancreatic cancer patients [122]. This evidence concerns the gene KMT2A and pancreatic neoplasm.